10.06.26 -- Structuring CGT Deals For The Long Term With Troutman Pepper Locke's EA Weeks, J.D., Ph.D.

Discussing the evolution of medium design for cell culture bioprocessing, and the role that multi-omics and bioinformatics can play in improved medium development.

 

Explore essential QC strategies in AAV gene therapy and learn how to address rcAAV detection, viral clearance per ICH Q5A, and impurity profiling using NGS to meet evolving regulatory demands.

Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Evaluate key considerations for advancing your therapy from concept to commercialization.

Achieve intuitive and successful automated cell therapy manufacturing by aligning stakeholder needs with a human-centered design and rigorous, real-world process validation.

This panel session features a decade-long story of a partnership that brought two life-changing gene therapies to market successfully in 2022. Hear from Kelly Kral, VP, CMC Strategy & Operations, bluebird bio, and Anthony Basile, Account Management CGT, Lonza.

In episode 138 of Cell & Gene: The Podcast, EA Weeks, J.D., Ph.D., Counsel at Troutman Pepper Locke talks to Host Erin Harris about the deal terms in CGT that matter most, including IP ownership, CMC milestones, manufacturing capacity, data rights, tech transfer, and more.